Vivus Inc (VVUS) 2.68 $VVUS
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)
Vivus: Qsymia Sales Dip - Is A Lower Price Needed?
Spencer Osborne - at Seeking Alpha - Sat Feb 07, 11:14PM CST
VVUS: 2.68 (+0.13)
Vivus' Qsymia Headed In The Wrong Direction
Clinically Sound Investor - at Seeking Alpha - Sat Feb 07, 4:44AM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Orexigen: Contrave Script Sales Dip. Why?
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:36PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena Scripts Grow, But Pace Is Slower Than Needed
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:31PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena's Belviq Keeps Up Momentum During A Flat Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 06, 3:05PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
With Flat Qsymia Sales, Vivus May Shift Focus To Stendra/Spedra
Spencer Osborne - at Seeking Alpha - Tue Feb 03, 1:44PM CST
NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Orexigen's Contrave Prescription Growth Slowing, But Still Good
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 5:37PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena Pharmaceuticals' Belviq Set To Surge In 2015
Jim Roof - at Seeking Alpha - Mon Feb 02, 12:47PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Despite the CDC's Best Efforts, This Disease Just Hit Record Levels
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 8:12AM CST
Source: Flickr user Next TwentyEight. Although cancer and heart disease may garner a significant portion of researchers' attention, obesity is a growing problem . According to estimates from the Centers for Disease Control and Prevention, more...
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), HWAY: 21.32 (+0.01), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena's Belviq Conquers MLK Week According To Symphony
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 7:38AM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Europe approves shorter dose time for Vivus' Stendra
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:49AM CST
VVUS: 2.68 (+0.13)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
Marketwired - Thu Jan 29, 6:02AM CST
VIVUS, Inc. (NASDAQ: VVUS) today announced that the European Commission (EC) has adopted the commission implementing decision amending the marketing authorization for SPEDRA (avanafil). SPEDRA is now the first and only erectile dysfunction (ED) medication approved in Europe that is indicated to be taken as needed approximately 15 to 30 minutes before sexual activity.
VVUS: 2.68 (+0.13)
Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?
Spencer Osborne - at Seeking Alpha - Wed Jan 28, 10:49AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Contrave Scripts Continue Increases For Orexigen
Spencer Osborne - at Seeking Alpha - Tue Jan 27, 2:33PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Newly Approved Weight Loss Method Works by Tricking Your Brain
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 25, 11:02AM CST
You can lose weight through plenty of methods. Dieting. Exercising. Taking weight-loss drugs. Undergoing gastric bypass surgery. The newest way, though, just might be the coolest and most revolutionary way of all. Source: EnteroMedics, ...
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)
Vivus: Qsymia Sales Dip - Is A Lower Price Needed?
Spencer Osborne - at Seeking Alpha - Sat Feb 07, 11:14PM CST
VVUS: 2.68 (+0.13)
Vivus' Qsymia Headed In The Wrong Direction
Clinically Sound Investor - at Seeking Alpha - Sat Feb 07, 4:44AM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Orexigen: Contrave Script Sales Dip. Why?
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:36PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena Scripts Grow, But Pace Is Slower Than Needed
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:31PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena's Belviq Keeps Up Momentum During A Flat Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 06, 3:05PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
With Flat Qsymia Sales, Vivus May Shift Focus To Stendra/Spedra
Spencer Osborne - at Seeking Alpha - Tue Feb 03, 1:44PM CST
NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Orexigen's Contrave Prescription Growth Slowing, But Still Good
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 5:37PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena Pharmaceuticals' Belviq Set To Surge In 2015
Jim Roof - at Seeking Alpha - Mon Feb 02, 12:47PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Despite the CDC's Best Efforts, This Disease Just Hit Record Levels
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 8:12AM CST
Source: Flickr user Next TwentyEight. Although cancer and heart disease may garner a significant portion of researchers' attention, obesity is a growing problem . According to estimates from the Centers for Disease Control and Prevention, more...
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), HWAY: 21.32 (+0.01), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena's Belviq Conquers MLK Week According To Symphony
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 7:38AM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Europe approves shorter dose time for Vivus' Stendra
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:49AM CST
VVUS: 2.68 (+0.13)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
Marketwired - Thu Jan 29, 6:02AM CST
VIVUS, Inc. (NASDAQ: VVUS) today announced that the European Commission (EC) has adopted the commission implementing decision amending the marketing authorization for SPEDRA (avanafil). SPEDRA is now the first and only erectile dysfunction (ED) medication approved in Europe that is indicated to be taken as needed approximately 15 to 30 minutes before sexual activity.
VVUS: 2.68 (+0.13)
Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?
Spencer Osborne - at Seeking Alpha - Wed Jan 28, 10:49AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Contrave Scripts Continue Increases For Orexigen
Spencer Osborne - at Seeking Alpha - Tue Jan 27, 2:33PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Newly Approved Weight Loss Method Works by Tricking Your Brain
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 25, 11:02AM CST
You can lose weight through plenty of methods. Dieting. Exercising. Taking weight-loss drugs. Undergoing gastric bypass surgery. The newest way, though, just might be the coolest and most revolutionary way of all. Source: EnteroMedics, ...
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
